← Comparing 1 hypotheses side-by-side
Add hypothesis:
— Select a hypothesis to add —
SULF-Mediated Protection of Cholinergic Tau Transport Pathwa (SULF1/SULF2) — 0.00 NLRP3/Autophagy Flux Enhancement in Astrocytes (TFEB) — 0.00 TBK1 Inhibitors as ALS Therapeutics: Targeting Downstream ST (TBK1) — 0.00 Enhancing Heparan Sulfate 3-O-Sulfotransferase Activity to C (HS3ST3A1/HS3ST3B1) — 0.00 Theta-Gamma Cross-Frequency Coupling Modulates lncRNA-9969 P (SST, FMRP, lncRNA-9969, ULK1) — 0.00 CYP2J2-Generated DHA Epoxides Enhance LXRβ-Mediated APOE Lip (CYP2J2) — 0.00 XOR+ stress-responsive astrocytes represent a novel AD-assoc (XOR) — 0.00 Rare TREM2-TYROBP pathway variants complement standard PRS b (PLCG2) — 0.00 AD fine-mapping identifies causal variants in microglia-spec (TREM2) — 0.00 Circulating hs-CRP as Disease-Modifying Target via Astrocyti (CRP → C3 → C3aR/C5aR axis) — 0.00 Magnetofection-Enhanced IGFBPL1 Delivery via Superparamagnet (IGFBPL1) — 0.00 CD38 Inhibition to Prevent NAD+ Depletion and Restore Cellul (CD38, SIRT1/3) — 0.00 NAD+-SIRT1-H3K9me3 restoration enables true senescence rever (SIRT1) — 0.00 Astrocyte-Mediated Synaptic Pruning to Optimize Functional C (C1q) — 0.00 SASP-Secreted MMP-9 from Senescent Microglia Disrupts Nuclea (MMP9 → NUP62/NUP88 → TARDBP mislocalization) — 0.00 Astroglial Gating of Microglial Ontogeny Switch (P2RY12) — 0.00 O-GlcNAcylation at T212 competes with phosphorylation to red (OGT) — 0.00 Tissue-specific interactome destabilization drives phenotype (%s) — 0.00 Mitochondrial DNA Release-STING Axis as Senolytic Efficacy P (CGAS, STING1, MT-DNA) — 0.00 Gut-derived butyrate reprograms microglia for amyloid cleara (HDAC2) — 0.00 Site-Specific TREM2 Fragment Analysis Within Multi-Analyte C (TREM2) — 0.00 CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metab (CCR2) — 0.00 TREM2-Mediated Microglial Regulation of Oligodendrocyte Prec (TREM2) — 0.00 Dynamic Plasma Exosome-Derived Multi-Analyte Panel Combining (CHI3L1/TREM2/NRGN) — 0.00 Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis (PRKAA1/PPARGC1A) — 0.00 Glucosylceramide accumulation nucleates alpha-synuclein aggr (GBA) — 0.00 Astrocytic MEGF10 Upregulation for Selective Synaptic Engulf (MEGF10) — 0.00 Plasma TREM2 Ectodomain Glycosylation Pattern as Therapeutic (TREM2/ST6GAL1/MGAT5) — 0.00 Heparan sulfate proteoglycan binding selectivity determines (SDC3 (Syndecan-3)) — 0.00 Kinetic Threshold Model Predicts CHIP-Mediated Clearance Req (STUB1) — 0.00
Add
|
× [Archived Hypothesis]
- · - · mechanistic
Composite 0.300
Price $0.30
Evidence For 0
Evidence Against 0
Radar Chart — 10 Dimensions
Score Breakdown
Dimension [Archived Hypothesis] Mechanistic 0.000 Evidence 0.000 Novelty 0.000 Feasibility 0.000 Impact 0.000 Druggability 0.000 Safety 0.000 Competition 0.000 Data 0.000 Reproducible 0.000 KG Connect 0.500
Evidence [Archived Hypothesis] No evidence citations yet
Debate Excerpts [Archived Hypothesis] 4 rounds · quality: 0.81
Theorist # Legacy Pre-Pipeline Hypotheses: Neurodegeneration
---
## Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
**Mechanism:** Misfolded α-synuclein (aSy...
Skeptic # Critical Evaluation of Legacy Pre-Pipeline Hypotheses
## General Methodological Concerns (Cross-Cutting Issues)
Before evaluating individual hypotheses, several systemic weaknesses affect the enti...
Domain Expert # Comprehensive Feasibility Assessment: Legacy Neurodegeneration Hypotheses
## Preamble
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidenc...
Synthesizer ```json
{
"ranked_hypotheses": [
{
"title": "TREM2-Deficient Microglia as Drivers of Amyloid Plaque Toxicity in Alzheimer's Disease",
"description": "TREM2 loss-of-function variants ...
Price History Overlay